Regeneron Pharmaceuticals Inc.
Moat Score — Regeneron Pharmaceuticals Inc.
Total Moat Score
14 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Regeneron's VelocImmune antibody-discovery platform, the Regeneron Genetics Center, and a deep patent estate behind Eylea and Dupixent constitute a genuine, hard-to-replicate scientific and regulatory moat that has produced over a dozen approved medicines. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Biologics manufacturing and R&D are capital- and expertise-intensive with no structural low-cost edge; Regeneron competes on innovation and efficacy rather than being a low-cost producer. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Blockbuster biologics historically command strong pricing, but Eylea's sharp erosion from biosimilars and IRA-driven Medicare price negotiation show that pricing power is real but increasingly contested and time-limited. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no mechanism by which additional patients or prescribers make Regeneron's drugs more valuable to other users; efficacy and safety data drive adoption, not network dynamics. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physicians and patients on a stable therapy regimen face some inertia to switching, and insurer formulary placement adds friction, but biosimilar and competitor drugs can and do displace incumbents once approved. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The scale of capital and scientific talent needed to originate and commercialize novel biologics limits the field of credible competitors, though large pharma rivals with deep pockets still contest every major franchise. |